{"id":"NCT02556788","sponsor":"Galderma R&D","briefTitle":"Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris","officialTitle":"A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2017-02-07","completion":"2017-05-12","firstPosted":"2015-09-22","resultsPosted":"2019-09-03","lastUpdate":"2019-11-12"},"enrollment":1212,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"CD5789 (trifarotene) 50µg/g Cream","otherNames":[]},{"type":"DRUG","name":"Placebo Cream","otherNames":[]}],"arms":[{"label":"CD5789 (Trifarotene) 50µg/g Cream","type":"EXPERIMENTAL"},{"label":"Placebo Cream","type":"PLACEBO_COMPARATOR"}],"summary":"Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.","primaryOutcome":{"measure":"Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)","timeFrame":"From Baseline to Week 12","effectByArm":[{"arm":"CD5789 (Trifarotene) 50µg/g Cream","deltaMin":255,"sd":null},{"arm":"Placebo Cream","deltaMin":157,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":81,"countries":["United States","Czechia","Hungary","Poland","Romania","Russia","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":602},"commonTop":["Application Site Irritation","Application Site Puritis","Application Site Pain","Application Site Dryness","Sunburn"]}}